In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Significant progress has been made in the past few years in the area of antibody drug
conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors. Early work in this …

Cancer is one of the deadliest diseases, causing million of deaths each year globally.
Conventional anti-cancer therapies are non-targeted and have systemic toxicities limiting …

Antibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as
compared to small cytotoxic molecules alone and have shown the evidence to overcome …

Abstract Antibody–drug conjugates (ADCs), which consist of three components, antibody,
linker, and payload, can function as “magic bullets”. These conjugates offer the ability to …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Highlights•ADC represents a new class of targeted anticancer therapeutics.•Elucidates
selection criteria for tumor specific antigen and ADC development.•Smart linkers and fixed …

The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …